HK Stock Market Move | ASCLETIS-B (01672) rose more than 5% as the global Phase III clinical trial for ASC30, used for long-term weight management, completed its first subject dosing.
Galactomyces Pharmaceuticals-B (01672) rose more than 5%. As of the time of writing, it has increased by 5.03%, priced at HKD 10.11, with a transaction volume of HKD 3.8431 million.
ASCLETIS-B (01672) surged over 5%, currently up 5.03%, trading at HKD 10.11, with a transaction volume of HKD 3.8431 million.
Recently, ASCLETIS-B announced that the global Phase III clinical trial for ASC30, aimed at long-term weight management, has completed its first dosing in a subject. ASC30 is an orally-administered small molecule GLP-1 receptor agonist proprietary to Ascletis, currently under clinical research, intended for long-term weight management and diabetes treatment.
The announcement stated that ASCLETIS-B expects to release the top-line data of the AURORA Phase III clinical trial in the third quarter of 2028. The company anticipates submitting its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) by the end of 2028 and plans to file its Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in early 2029. Ascletis maintains a robust balance sheet and ample cash on hand to cover the regulatory submissions planned for the U.S. and Europe, supporting the company's operations through 2029.
Related Articles
HK Stock Market Move | Biocytogen Pharmaceuticals-B (02315) surged over 13% as its core business maintained rapid growth in the first half of the year, with AI empowerment accelerating the realization of its platform.
HK Stock Market Move | The shares of domestic property developers continue to decline, as the real estate development sector ushers in a new model. The business model of real estate companies and their valuation anchors are facing a reassessment.
HK Stock Market Move | DUIBA (01753) rose over 46% during the trading session, with revenue in the first half of the year increasing by 24.34% year-on-year. The cumulative views of AI short dramas across the internet have exceeded 5 billion.
HK Stock Market Move | Biocytogen Pharmaceuticals-B (02315) surged over 13% as its core business maintained rapid growth in the first half of the year, with AI empowerment accelerating the realization of its platform.
HK Stock Market Move | The shares of domestic property developers continue to decline, as the real estate development sector ushers in a new model. The business model of real estate companies and their valuation anchors are facing a reassessment.
HK Stock Market Move | DUIBA (01753) rose over 46% during the trading session, with revenue in the first half of the year increasing by 24.34% year-on-year. The cumulative views of AI short dramas across the internet have exceeded 5 billion.
RECOMMEND
